An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models

Clinical and Vaccine Immunology

Volumn 20, Issue 1, 2013, Pages 85-94

  Scallan, Ciaran D ^a   Tingley, Debora W ^a   Lindbloom, Jonathan D ^a   Toomey, James S ^b   Tucker, Sean N ^a  

^a Vaxart Inc   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DOUBLE STRANDED RNA; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ DOUBLE STRANDED RNA FUSION PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FERRET; INFLUENZA A (H5N1); MALE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FERRETS; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RNA, DOUBLE-STRANDED; VACCINES, SYNTHETIC;

EID: 84872231984     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00552-12     Document Type: Article

References (44)

1. WHO. 2006. R & D for avian/pandemic influenza vaccines by IFPMA Influenza International Supply Task Force (IVS ITF) members. http://www.who.int/vaccine-research/diseases/influenza/IFPMA-Avian-Pandemic- Influenza-Vaccine-R&D.pdf.
2. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2012. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336:1534-1541.
3. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y. 2012. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486:420-428.
4. Tucker SN, Tingley DW, Scallan CD. 2008. Oral adenoviral-based vaccines: historical perspective and future opportunity. Expert Rev. Vaccines 7:25-31.
5. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC. 2003. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. 77:10780-10789.
6. Cheng X, Ming X, Croyle MA. 2003. PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route. Pharm. Res. 20:1444-1451.
7. Mutwiri G, Watts T, Lew L, Beskorwayne T, Papp Z, Baca-Estrada ME, Griebel P. 1999. Ileal and jejunal Peyer's patches play distinct roles in mucosal immunity of sheep. Immunology 97:455-461.
8. Lubeck MD, Davis AR, Chengalvala M, Natuk RJ, Morin JE, Molnar-Kimber K, Mason BB, Bhat BM, Mizutani S, Hung PP. 1989. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl. Acad. Sci. U. S. A. 86:6763-6767.
9. Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KH, Rappuoli R, Del Giudice G. 2001. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534-2541.
10. Nishiya T, Kajita E, Miwa S, Defranco AL. 2005. TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J. Biol. Chem. 280:37107-37117.
11. Cario E, Podolsky DK. 2000. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68:7010-7017.
12. Phillpotts RJ, O'Brien L, Appleton RE, Carr S, Bennett A. 2005. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine 23:1615-1623.
13. Jordan M, Schallhorn A, Wurm FM. 1996. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 24:596-601.
14. Suzuki E, Murata T, Watanabe S, Kujime Y, Hirose M, Pan J, Yamazaki T, Ugai H, Yokoyama KK. 2004. A simple method for the simultaneous detection of E1A and E1B in adenovirus stocks. Oncol. Rep. 11:173-178.
15. Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y. 2001. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. U. S. A. 98:11539-11544.
16. Sharpe S, Fooks A, Lee J, Hayes K, Clegg C, Cranage M. 2002. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. Virology 293:210-216.
17. Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. 2002. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76:243-250.
18. Tucker SN, Lin K, Stevens S, Scollay R, Bennett MJ, Olson DC. 2003. Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland. Mol. Ther. 8:392-399.
19. Croyle MA, Chirmule N, Zhang Y, Wilson JM. 2001. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75:4792-4801.
20. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, Couto LB, Pierce GF. 2006. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107:1810-1817.
21. Holman DH, Wang D, Raja NU, Luo M, Moore KM, Woraratanadharm J, Mytle N, Dong JY. 2008. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine 26:2627-2639.
22. Kariko K, Bhuyan P, Capodici J, Weissman D. 2004. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172:6545-6549.
23. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, Hanh TH, Puthavathana P, Long HT, Buranathai C, Lim W, Webster RG, Hoffmann E. 2005. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J. Virol. 79:2191-2198.
24. Smith H, Sweet C. 1988. Lessons for human influenza from pathogenicity studies with ferrets. Rev. Infect. Dis. 10:56-75.
25. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC. 2006. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657-1664.
26. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354:1343-1351.
27. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus AD. 2008. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 3:e1401. doi:10.1371/journal.pone.0001401.
28. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A. 2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11:351-357.
29. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, Robbins PD, Swayne DE, Donis RO, Katz JM, Barratt-Boyes SM, Gambotto A. 2006. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80:1959-1964.
30. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK, Sambhara S. 2006. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367:475-481.
31. Tang M, Harp JA, Wesley RD. 2002. Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2). Arch. Virol. 147:2125-2141.
32. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH. 2006. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239-243.
33. Pandey A, Singh N, Vemula SV, Couetil L, Katz JM, Donis R, Sambhara S, Mittal SK. 2012. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One 7:e33428. doi:10.1371/journal.pone.0033428.
34. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljeström P, Reis e Sousa C. 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433:887-892.
35. Top FH, Jr, Buescher EL, Bancroft WH, Russell PK. 1971. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J. Infect. Dis. 124:155-160.
36. Knopf HL, Blacklow NR, Glassman MI, Cline WL, Wong VG. 1971. Antibody in tears following intranasal vaccination with inactivated virus. II. Enhancement of tear antibody production by the use of polyinosinic: polycytidilic acid (poly I:C). Invest. Ophthalmol. 10:750-759.
37. Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y, Schlesinger SJ, Colonna M, Steinman RM. 2008. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl. Acad. Sci. U. S. A. 105:2574-2579.
38. Li D, Liu Y, Zhang Y, Xu J, Hong K, Sun M, Shao Y. 2007. Adjuvant effects of plasmid-generated hairpin RNA molecules on DNA vaccination. Vaccine 25:6992-7000.
39. Nociari M, Ocheretina O, Schoggins JW, Falck-Pedersen E. 2007. Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J. Virol. 81:4145-4157.
40. Zhu J, Huang X, Yang Y. 2007. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and-independent pathways. J. Virol. 81:3170-3180.
41. Mutwiri G, Bateman C, Baca-Estrada ME, Snider M, Griebel P. 2000. Induction of immune responses in newborn lambs following enteric immunization with a human adenovirus vaccine vector. Vaccine 19:1284-1293.
42. Melmed G, Thomas LS, Lee N, Tesfay SY, Lukasek K, Michelsen KS, Zhou Y, Hu B, Arditi M, Abreu MT. 2003. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J. Immunol. 170:1406-1415.
43. Shibolet O, Podolsky DK. 2007. TLRs in the gut IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Am. J. Physiol. Gastrointest. Liver Physiol. 292:G1469-G1473.
44. Contractor N, Louten J, Kim L, Biron CA, Kelsall BL. 2007. Cutting edge: Peyer's patch plasmacytoid dendritic cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGFbeta, and prostaglandin E2 in conditioning a unique mucosal pDC phenotype. J. Immunol. 179:2690-2694.